000143405 001__ 143405
000143405 005__ 20240229112551.0
000143405 0247_ $$2doi$$a10.1016/j.canep.2019.01.003
000143405 0247_ $$2pmid$$apmid:30690330
000143405 0247_ $$2ISSN$$a1877-7821
000143405 0247_ $$2ISSN$$a1877-783X
000143405 037__ $$aDKFZ-2019-00993
000143405 041__ $$aeng
000143405 082__ $$a610
000143405 1001_ $$aBenzarti, Sonia$$b0
000143405 245__ $$aTrends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.
000143405 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2019
000143405 3367_ $$2DRIVER$$aarticle
000143405 3367_ $$2DataCite$$aOutput Types/Journal article
000143405 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1575968532_1465
000143405 3367_ $$2BibTeX$$aARTICLE
000143405 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143405 3367_ $$00$$2EndNote$$aJournal Article
000143405 520__ $$aChronic myelomonocytic leukemia (CMML) is a rare hematopoietic malignancy. Treatment with hypomethylating agents (HMA) was introduced between 2004 and 2006 but its impact on population-based survival remains controversial. The aim of this study was to investigate epidemiological characteristics and survival before and after introduction of HMA treatment.We performed a population-based analysis of CMML cases reported to the Cantonal Cancer Registries in Switzerland (SWISS) and the Surveillance, Epidemiology, and End Results (SEER) Program from the United States for 1999-2006 (before HMA) and 2007-2014 (after HMA). Time trends were compared for these two time periods.423 and 4144 new CMML cases were reported to the SWISS and SEER registries, respectively. We observed an increasing proportion of older patients ≥75 years in the SWISS (50.3%-62.3%) compared to a decreasing one in the SEER population (59.1%-55.1%). Age standardized incidence-rates were similar and remained stable in both countries (0.32-0.38 per 100'000 py). Relative survival (RS) improved significantly in the SEER (3 years 27%-37%; 5 years 19%-23%; p < 0.001 for both) but remained stable in the SWISS population (3 years 48% to 40%; 5 years 34% to 26%; n.s. for both).With the exception of opposing age-trends, epidemiologic characteristics are similar in both countries and comparable to other population-based registries. RS remains poor and different time trends of population-based survival cannot be faithfully explained by HMA but most likely by changes in diagnostic accuracy within prognostically distinct age-groups.
000143405 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143405 588__ $$aDataset connected to CrossRef, PubMed,
000143405 7001_ $$aDaskalakis, Michael$$b1
000143405 7001_ $$aFeller, Anita$$b2
000143405 7001_ $$aBacher, Vera Ulrike$$b3
000143405 7001_ $$aSchnegg-Kaufmann, Annatina$$b4
000143405 7001_ $$aRüfer, Axel$$b5
000143405 7001_ $$aHolbro, Andreas$$b6
000143405 7001_ $$aSchmidt, Adrian$$b7
000143405 7001_ $$aBenz, Rudolf$$b8
000143405 7001_ $$aSolenthaler, Max$$b9
000143405 7001_ $$aStussi, Georg$$b10
000143405 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b11$$udkfz
000143405 7001_ $$aBonadies, Nicolas$$b12
000143405 7001_ $$aGroup, NICER Working$$b13$$eCollaboration Author
000143405 773__ $$0PERI:(DE-600)2498032-8$$a10.1016/j.canep.2019.01.003$$gVol. 59, p. 51 - 57$$p51 - 57$$tCancer epidemiology$$v59$$x1877-7821$$y2019
000143405 909CO $$ooai:inrepo02.dkfz.de:143405$$pVDB
000143405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000143405 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143405 9141_ $$y2019
000143405 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143405 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143405 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEMIOL : 2017
000143405 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143405 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143405 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143405 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143405 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143405 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143405 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143405 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143405 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143405 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lCancer Survivorship$$x0
000143405 980__ $$ajournal
000143405 980__ $$aVDB
000143405 980__ $$aI:(DE-He78)C071-20160331
000143405 980__ $$aUNRESTRICTED